Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 8/20 | 0.43 |
| ▸ | KDR | P35968 | 7/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.40 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.39 |
| ▸ | TNF | P01375 | 1/20 | 0.38 |
| ▸ | PGK1 | P00558 | 1/20 | 0.37 |
| ▸ | WHR1 | P49842 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL294809 | 0.87 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1HTTEGFRKDR | |
| SCHEMBL29532044 | 0.87 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1HTTEGFRKDR | |
| SCHEMBL8094835 | 0.83 | POLB (0.48) | SMN1; SMN2ALDH1A1HTTEGFRKDR | |
| Propanol SCHEMBL28411721 | 0.78 | HTT (0.60) | SMN1; SMN2ALDH1A1HTTEGFRKDR | |
| SCHEMBL10958235 | 0.77 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1HTTEGFRKDR | |
| SCHEMBL30615149 | 0.77 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1HTTEGFRKDR | |
| SCHEMBL30615130 | 0.77 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1HTTEGFRKDR | |
| SCHEMBL27248760 | 0.77 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1HTTEGFRKDR | |
| SCHEMBL7162825 | 0.76 | SMN1; SMN2 (0.39) | SMN1; SMN2ALDH1A1HTTEGFRKDR | |
| SCHEMBL7164352 | 0.76 | ENPP1 (0.56) | SMN1; SMN2ALDH1A1HTTEGFRKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039473-A1 | PREPARATION AND UTILITY OF SUBSTITUTED QUINAZOLINE COMPOUNDS WITH ALPHA-ADRENERGIC BLOCKING EFFECTS | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039473-A1 | PREPARATION AND UTILITY OF SUBSTITUTED QUINAZOLINE COMPOUNDS WITH ALPHA-ADRENERGIC BLOCKING EFFECTS | ADRB1, ADRB2, ADRB3 | SMN1; SMN2 4435/4885ALDH1A1 848/4885HTT 4597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.